Tralokinumab is a humanized monoclonal antibody that binds to IL-13 and inhibits the interaction of IL-13 and its receptor. Tralokinumab has been used for the treatment of atopic dermatitis (AD).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.